Richard B. Racine

Rich's practice involves virtually all aspects of intellectual property law, with a particular emphasis on district court patent litigation, inter partes reviews (IPR) at the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office (USPTO), due diligence investigations, and opinion matters. He works closely with clients in a variety of technologies to develop and execute strategies that best obtain, protect, and enforce their intellectual property.

Rich has extensive litigation experience and has had key responsibilities in federal district court cases, from the initial pleading stage through discovery, motions, claim construction, and trial. Much of his litigation practice involves complex and significant patent infringement disputes. He has held lead roles in Abbreviated New Drug Application (ANDA) litigations for blockbuster pharmaceuticals and has a keen understanding of the interplay of the Hatch-Waxman Act, the patent laws, and the Food and Drug Administration (FDA) rules. Over the past few years, Rich has represented petitioners and patent owners in over a dozen IPRs involving commercially important vaccines and pharmaceuticals.

Rich has a robust and sophisticated opinion and due diligence practice involving a wide range of technologies, with a specific focus in the pharmaceutical and chemical areas. He has rendered countless opinions on complex patent validity, enforceability, and infringement questions. Many of these opinions were in anticipation of litigation, or as part of mergers, acquisitions, due diligence investigations, patent portfolio assessments and development, or licensing opportunities.

Rich frequently lectures on patent protection and litigation, especially opinion and due diligence practice, and the American Invents Act (AIA). He has chaired and lectured various meetings and programs hosted by organizations, including the Practice Resources Group, Managing Intellectual Property (MIP), Intellectual Property Owners Association (IPO), the Biotechnology Innovation Organization (BIO), the Hildebrandt Institute, the Food and Drug Law Institute (FDLI), CEC Fortune 500 Conference, and the Southwestern Legal Foundation.

Rich has held numerous management and leadership roles in the firm. He served as the firm's chairman, following his tenure as managing partner. He has been a member of both the management and compensation committees, and he led the firms chemical practice group for two terms. Currently, Rich serves as Finnegan's Loss Prevention Counsel, focusing on ethics, conflicts, and loss prevention issues.